SAB Biotherapeutics (SABS) Competitors $2.32 -0.18 (-7.20%) As of 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SABS vs. CRIS, BOLT, AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, and INCYShould you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Curis (CRIS), Bolt Biotherapeutics (BOLT), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), and Incyte (INCY). These companies are all part of the "biotechnology" industry. SAB Biotherapeutics vs. Its Competitors Curis Bolt Biotherapeutics Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Curis (NASDAQ:CRIS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has better valuation and earnings, CRIS or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Curis. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCuris$10.91M1.78-$43.39M-$4.88-0.32SAB Biotherapeutics$1.32M18.30-$34.10M-$4.00-0.58 Which has more volatility & risk, CRIS or SABS? Curis has a beta of 3.86, meaning that its share price is 286% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Does the media favor CRIS or SABS? In the previous week, Curis had 2 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 3 mentions for Curis and 1 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.91 beat Curis' score of 0.64 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Curis Positive SAB Biotherapeutics Very Positive Do analysts recommend CRIS or SABS? Curis presently has a consensus price target of $17.00, suggesting a potential upside of 996.77%. SAB Biotherapeutics has a consensus price target of $9.33, suggesting a potential upside of 302.30%. Given Curis' higher probable upside, analysts plainly believe Curis is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00SAB Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is CRIS or SABS more profitable? SAB Biotherapeutics has a net margin of 0.00% compared to Curis' net margin of -341.24%. Curis' return on equity of 0.00% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Curis-341.24% N/A -102.22% SAB Biotherapeutics N/A -153.92%-89.16% Do insiders and institutionals have more ownership in CRIS or SABS? 30.0% of Curis shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 5.5% of Curis shares are held by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummarySAB Biotherapeutics beats Curis on 10 of the 17 factors compared between the two stocks. Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SABS vs. The Competition Export to ExcelMetricSAB BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.15M$3.31B$6.03B$10.35BDividend YieldN/A2.29%5.66%4.69%P/E Ratio-0.5822.1685.4326.75Price / Sales18.30411.22584.59179.25Price / CashN/A47.1938.3262.20Price / Book0.8310.2512.766.61Net Income-$34.10M-$52.40M$3.30B$275.78M7 Day Performance12.62%1.52%1.60%-0.43%1 Month Performance8.92%13.07%8.18%6.31%1 Year Performance-7.94%31.03%80.39%33.17% SAB Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SABSSAB Biotherapeutics4.1597 of 5 stars$2.32-7.2%$9.33+302.3%-7.4%$24.15M$1.32M-0.58140Positive NewsCRISCuris2.2353 of 5 stars$1.64-1.5%$17.00+939.8%-68.1%$20.44M$11.41M-0.3460Positive NewsAnalyst ForecastBOLTBolt Biotherapeutics2.8589 of 5 stars$5.28+0.3%$47.50+800.5%-53.9%$10.12M$7.69M-0.2090Analyst ForecastAMGNAmgen4.553 of 5 stars$276.30+0.9%$309.70+12.1%-8.4%$151.17B$33.42B22.9628,000Positive NewsAnalyst UpgradeAnalyst RevisionGILDGilead Sciences4.8943 of 5 stars$111.87-0.7%$117.17+4.7%+35.5%$141.21B$28.75B22.6717,600Trending NewsAnalyst ForecastAnalyst RevisionVRTXVertex Pharmaceuticals4.8159 of 5 stars$387.56-2.0%$493.81+27.4%-11.3%$99.88B$11.02B27.856,100Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.7218 of 5 stars$557.58-0.6%$817.67+46.6%-43.7%$59.67B$14.21B14.1915,106Positive NewsAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.0001 of 5 stars$452.44+1.1%$439.58-2.8%+68.7%$59.34B$2.25B-183.272,230Analyst ForecastBIIBBiogen4.6607 of 5 stars$137.34-0.9%$182.04+32.5%-19.5%$20.33B$9.68B13.267,605Trending NewsAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.3219 of 5 stars$420.34-0.9%$449.57+7.0%+24.8%$19.01B$2.88B16.451,305Analyst ForecastInsider TradeINCYIncyte4.507 of 5 stars$84.35+0.5%$83.67-0.8%+28.9%$16.48B$4.24B19.182,617Analyst Forecast Related Companies and Tools Related Companies CRIS Competitors BOLT Competitors AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SABS) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsoleteWhen a new chip can run at the speed of light, the game changes. This is the reality of “TF3” — a man-made...The Oxford Club | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
